Search Within

Kenneth K Ng

  1. "Radiology, Department of"
Formats
  1. Journal Article (9)
  2. Meeting Abstract (9)
Groups
  1. Department of Medicine (18)
  2. Radiology, Department of (18)
  3. Solid Tumor Oncology Division (18)
  4. Thoracic Oncology (18)
  5. Body Imaging Service (12)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (12)

More Groups

People
  1. Charles Rudin (11)
  2. Juliana Eng (9)
  3. Afsheen Iqbal (6)
  4. David Pfister (6)
  5. Eric Sherman (6)
  6. Mark Kris (6)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2022 (2)
  4. 2021 (1)
  5. 2020 (2)
  6. 2018 (3)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Clinical Cancer Research (3)
  3. International Journal of Radiation Oncology, Biology, Physics (2)
  4. Journal of Thoracic Oncology (2)
  5. Nature Medicine (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (5)
  2. American Association for Cancer Research (4)
  3. Elsevier Inc. (4)
  4. Nature Publishing Group (2)
  5. Elsevier Ireland Ltd. (1)
  6. Harborside Press (1)

More Publishers

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers
    Journal Article

    Drilon, A.; Somwar, R.; Mangatt, B. P.; Edgren, H.; Desmeules, P.; Ruusulehto, A.; Smith, R. S.; Delasos, L.; Vojnic, M.; Plodkowski, A. J.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer
    Journal Article

    Pietanza, M. C.; Litvak, A. M.; Varghese, A. M.; Krug, L. M.; Fleisher, M.; Teitcher, J. B.; Holodny, A. I.; Sima, C. S.; Woo, K. M.; Ng, K. K.; more...
    Lung Cancer (2016)

    Fulltext@MSK | Save
  • Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC)
    Meeting Abstract

    Pietanza, M. C.; Krug, L. M.; Varghese, A. M.; Fleisher, M.; Teitcher, J. B.; Holodny, A.; Sima, C. S.; Litvak, A. M.; Ng, K. K.; Patel, P. R.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC)
    Journal Article

    Fury, M. G.; Sherman, E. J.; Rao, S. S.; Wolden, S.; Smith-Marrone, S.; Mueller, B.; Ng, K. K.; Dutta, P. R.; Gelblum, D. Y.; Lee, J. L.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Phase I study of weekly albumin-bound paclitaxel (ab-P) plus weekly cetuximab (Cet) plus intensity-modulated radiation therapy (IMRT) in patients with stage III/IVb head and neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Fury, M. G.; Sherman, E. J.; Rao, S. S.; Wolden, S. L.; Smith-Marrone, S.; Ng, K. K.; Mueller, B.; Gelblum, D. Y.; Dutta, P. R.; Lee, J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
    Journal Article

    Fury, M. G.; Sherman, E.; Lisa, D.; Agarwal, N.; Algazy, K.; Brockstein, B.; Langer, C.; Lim, D. ; Mehra, R.; Rajan, S. K.; more...
    Journal of the National Comprehensive Cancer Network (2012)

    Fulltext@MSK | Save
  • A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m(2) for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Meeting Abstract

    Fury, M. G.; Sherman, E. J.; Lisa, D. M.; Agarwal, N.; Algazy, K. M.; Brockstein, B.; Langer, C. J.; Lim, D.; Mehra, R.; Rajan, S. K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • 10-Propargyl-10-deazaaminopterin: An antifolate with activity in patients with previously treated non-small cell lung cancer
    Journal Article

    Krug, L. M.; Azzoli, C. G.; Kris, M. G.; Miller, V. A.; Khokhar, N. Z.; Tong, W.; Ginsberg, M. S.; Venkatraman, E.; Tyson, L.; Pizzo, B.; more...
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save